Current Treatment Options in Neurology

Papers
(The TQCC of Current Treatment Options in Neurology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Tau in Multiple Sclerosis: A Review of Therapeutic Potential91
Role of Gut Microbiome in Depression36
Epilepsy as a Wilding of Sleep34
Race/Ethnicity Considerations in the Prevention and Treatment of Stroke26
Update on Stroke Prevention and Treatment in Patients with Antiphospholipid Antibody Syndrome21
Postoperative Neurosurgical Complications in Neurocritical Care21
The Effect of Obstructive Sleep Apnea on Cognition: A Focus on Decision-Making17
Clinical Applications of Non-Invasive Brain Stimulation in Stroke Recovery: A Review of Current Evidence and Therapeutic Strategies16
Delving Into the Significance of Brain’s Collateral Circulation in the Era of Revascularization Therapy11
Genetic Testing for Epilepsy: A User Guide11
Mechanical Thrombectomy for Acute Ischemic Stroke: Current State and Future Directions10
Education and Team Science in Neurocritical Care9
Practical Approaches to the Treatment of Neonatal Seizures9
Strategic De-escalation of Disease-Modifying Therapies in Elderly Patients: Approaches and Considerations9
MOG-IgG Associated Disease (MOG-AD) in Adults8
Dual Antiplatelet Therapy in Ischemic Stroke Prevention: Which Two Could Be Better than One?8
Ultrasound-Guided Therapies in the Neuro ICU8
Accessing Investigational Products Outside of a Trial: Considerations for Neuromuscular Providers6
Advanced Imaging in the Era of Tissue-Based Treatment for Acute Ischemic Stroke—a Practical Review5
Update on the Diagnostic and Therapeutic Landscape of Sporadic Inclusion Body Myositis4
Temperature Control in Hypoxic-Ischemic Brain Injury—a Focused Update4
Current Treatment Options for Patients with Myotonic Dystrophy Type 24
Gut Microbiome as Potential Therapeutics in Multiple Sclerosis4
A Review of Adult-Onset Hearing Loss: a Primer for Neurologists4
Brain-Lung Crosstalk: Management of Concomitant Severe Acute Brain Injury and Acute Respiratory Distress Syndrome3
Correction to: Diagnosis and Management of Posterior Cortical Atrophy3
Rescue Medications for Acute Repetitive Seizures3
Update on Paraneoplastic Neuromuscular Disorders3
Fenfluramine for the Treatment of Dravet Syndrome and Lennox Gastaut Syndrome: A Review3
The Impact of Epstein-Barr Virus on Autoimmune Neuromuscular Disorders: A Comparative Study of Myasthenia Gravis and Guillain–Barre Syndrome3
Evaluation and Management of Delirium in Dementia3
Article Topic: Neuropathies Due to Infections and Antimicrobial Treatments3
Shared Decision-Making and Family Meetings in Neurocritical Care3
Update on Simulation in Neurocritical Care – Current Applications and Future Directions2
Acute Stroke Treatment in an Anticoagulated Patient: When Is Thrombolysis an Option?2
Treatment of Obstructive Sleep Apnea in patients with Alzheimer’s Disease: role of Continuous Positive Airway Pressure therapy2
Pharmacologic Approaches to Insomnia and Other Sleep Disorders in Children2
Reducing Sudden Unexpected Death in Epilepsy: Considering Risk Factors, Pathophysiology and Strategies2
Progressive Supranuclear Palsy Diagnosis and Treatment2
Treatment of Vascular Myelopathies2
The Current Role of Valproic Acid in the Treatment of Epilepsy: A Glimpse into the Present of an Old Ally2
Self-care and Epilepsy2
Neurocritical Care of the Pregnant Patient2
Updated Review of Leber Hereditary Optic Neuropathy2
Updates in Fluid, Tissue, and Imaging Biomarkers for Dementia with Lewy Bodies and Implications for Biologically Based Disease Definitions2
A Review of the Current Literature and Updates on Embolic Stroke of Undetermined Source (ESUS)2
TINNITUS. A Non-invasive Neuromodulatory Perspective2
Update on Therapy for Myotonic Dystrophy Type 12
Treatment of Symptomatic Carotid Webs: Current Evidence and Future Directions2
Best Practices for Seizure Treatment in Oncology Patients2
0.05660080909729